🚀 VC round data is live in beta, check it out!
Cellectar Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cellectar Biosciences and similar public comparables like Annexin Pharmaceuticals, Longeveron, Chemomab Therapeutics, Exact Therapeutics and more.
Cellectar Biosciences Overview
About Cellectar Biosciences
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Founded
1996
HQ
Employees
11
Website
Sectors
Financials (LTM)
EV
$101K
Cellectar Biosciences Financials
Cellectar Biosciences reported last 12-month revenue of —.
In the same LTM period, Cellectar Biosciences generated had net loss of ($23M).
Revenue (LTM)
Cellectar Biosciences P&L
In the most recent fiscal year, Cellectar Biosciences reported revenue of — and EBITDA of ($23M).
Cellectar Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($23M) | XXX | XXX | XXX |
| Net Profit | ($23M) | XXX | ($22M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cellectar Biosciences Stock Performance
Cellectar Biosciences has current market cap of $12M, and enterprise value of $101K.
Market Cap Evolution
Cellectar Biosciences' stock price is $2.76.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $101K | $12M | 0.0% | XXX | XXX | XXX | $-5.14 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCellectar Biosciences Valuation Multiples
Cellectar Biosciences trades at 0.0x EV/EBITDA.
EV / Revenue (LTM)
Cellectar Biosciences Financial Valuation Multiples
As of March 21, 2026, Cellectar Biosciences has market cap of $12M and EV of $101K.
Equity research analysts estimate Cellectar Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cellectar Biosciences has a P/E ratio of (0.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12M | XXX | $12M | XXX | XXX | XXX |
| EV (current) | $101K | XXX | $101K | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 0.0x | XXX | XXX | XXX |
| EV/EBIT | 0.0x | XXX | 0.0x | XXX | XXX | XXX |
| P/E | (0.5x) | XXX | (0.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 0.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cellectar Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cellectar Biosciences Margins & Growth Rates
Cellectar Biosciences' revenue in the last fiscal year grew by —.
Cellectar Biosciences' revenue per employee in the last FY averaged $0.0M.
Cellectar Biosciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (56%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cellectar Biosciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Annexin Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Longeveron | XXX | XXX | XXX | XXX | XXX | XXX |
| Chemomab Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Exact Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Alligator Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cellectar Biosciences M&A Activity
Cellectar Biosciences acquired XXX companies to date.
Last acquisition by Cellectar Biosciences was on XXXXXXXX, XXXXX. Cellectar Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cellectar Biosciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCellectar Biosciences Investment Activity
Cellectar Biosciences invested in XXX companies to date.
Cellectar Biosciences made its latest investment on XXXXXXXX, XXXXX. Cellectar Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cellectar Biosciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cellectar Biosciences
| When was Cellectar Biosciences founded? | Cellectar Biosciences was founded in 1996. |
| Where is Cellectar Biosciences headquartered? | Cellectar Biosciences is headquartered in United States. |
| How many employees does Cellectar Biosciences have? | As of today, Cellectar Biosciences has over 11 employees. |
| Who is the CEO of Cellectar Biosciences? | Cellectar Biosciences' CEO is James V. Caruso. |
| Is Cellectar Biosciences publicly listed? | Yes, Cellectar Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Cellectar Biosciences? | Cellectar Biosciences trades under CLRB ticker. |
| When did Cellectar Biosciences go public? | Cellectar Biosciences went public in 2005. |
| Who are competitors of Cellectar Biosciences? | Cellectar Biosciences main competitors are Annexin Pharmaceuticals, Longeveron, Chemomab Therapeutics, Exact Therapeutics. |
| What is the current market cap of Cellectar Biosciences? | Cellectar Biosciences' current market cap is $12M. |
| Is Cellectar Biosciences profitable? | No, Cellectar Biosciences is not profitable. |
| What is the current net income of Cellectar Biosciences? | Cellectar Biosciences' last 12 months net income is ($23M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.